TransEnterix to Feature Senhance™ Surgical Robot at American Association of Gynecologic Laparoscopists
Showcasing new robot at the leading association of minimally invasive gynecology
The Senhance will be available for surgeon evaluations at the congress.
Surgeons may schedule system evaluations by signing up at the
The Senhance carries the CE Mark for use in general surgery, gynecology,
urology and thoracic surgery but is not available for sale in the US.
Forward Looking Statements
This press release includes statements relating to The Senhance™
Surgical Robotic System and our current regulatory and commercialization
plans for this product. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are subject to
risks and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations, including whether and when we will prepare a 510(k)
submission for the Senhance Surgical Robotic System. For a discussion of
the risks and uncertainties associated with
(For EU) Conrad Harrington, +44 (0)20 3178 8914
News Provided by Acquire Media